Tachycardia, VentricularOMNINCT00277524
OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.
An observational study of Tachycardia, Ventricular and Heart Failure, Congestive, run by Medtronic Cardiac Rhythm and Heart Failure at 113 sites in United States.
Trial summary
The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tachycardia, Ventricular, Heart Failure, Congestive, Ventricular Fibrillation
- How many people
- 3,032 participants
- Where
- 113 sitesUnited States
- Study dates
- Aug 2005to Nov 2010
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients receiving a specified Medtronic Implantable Pulse Generator(IPG), Implantable Cardioverter Defibrillator(ICD), or Cardiac Resynchronization Therapy-Defibrillator(CRT-D) device where informed consent and/or authorization to use and disclose health information permission has been granted.
Who may be able to join
- Implant of new or replacement study device. Enrollment must occur no later than 40 days post-implant.
- Study participants must be 18 years of age or older.
Who cannot join
- Study participants enrolled or intend to participate in another clinical device trial during the course of this study that required specific treatment or programming.
- Study participants unwilling and unable to comply with follow-up schedule.
Trial locations and contacts
113 sites in 1 country.
113 sites in 1 country
United States113 sites
Albany Associates in Cardiology
Albany, New York, 12205-1438
Altoona Regional Health Center
Altoona, Pennsylvania, 16601-4804
Amarillo Heart Group
Amarillo, Texas, 79106-2430
University of Michigan Health System (UMHS) VA Medical Center
Ann Arbor, Michigan, 48105-2303
Cardiology Associates PC
Annapolis, Maryland, 21401
King's Daughters Medical Center
Ashland, Kentucky, 41101-2843
Emory University Hospital
Atlanta, Georgia, 30322
Bluestem Cardiology PC
Bartlesville, Oklahoma, 74006
Cardio Research of New York Inc
Bayside, New York, 11361
Midwest Cardiology PC
Belleville, Illinois, 62226
Rocky Mountain Cardiology PC
Boulder, Colorado, 80304
Cardiovascular Consultants (Cape Giradeau MO)
Cape Girardeau, Missouri, 63703
Cardiologists PC
Cedar Rapids, Iowa, 52403
CAMC Institute Clinical Trials Center
Charleston, West Virginia, 25304
Sanger Heart and Vascular Institute-Charlotte
Charlotte, North Carolina, 28203
TriHealth Good Samaritan Hos
Cincinnati, Ohio, 45220-2475
Pikes Peak Cardiology
Colorado Springs, Colorado, 80909
Columbia Heart Clinic PA
Columbia, South Carolina, 29203
Cardiovascular Associates LLC
Covington, Louisiana, 70433
Dallas VA Medical Center
Dallas, Texas, 75216
Daytona Heart
Daytona Beach, Florida, 32114
New Jersey Heart (Elizabeth NJ)
Elizabeth, New Jersey, 07202
Cardiovascular Associates
Elk Grove Village, Illinois, 60007
EMH Elyria Medical Center
Elyria, Ohio, 44035
Englewood Hospital & Medical Center
Englewood, New Jersey, 07631
The Heart Group PC
Evansville, Indiana, 47710-1656
Internal Medicine & Cardiology Associates of Southeastern New England PC
Fall River, Massachusetts, 02720
Pee Dee Cardiology
Florence, South Carolina, 29506
Florida Arrhythmia Consultants
Fort Lauderdale, Florida, 33308
Cardiovascular Specialists of Frederick
Frederick, Maryland, 21702
California Heart Medical Associates
Fresno, California, 93720
Heart Care Inc
Gahanna, Ohio, 43230
Northeast Georgia Heart Center PC
Gainesville, Georgia, 30501
The Heart Center
Glen Burnie, Maryland, 21061-5613
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Altru Hospital
Grand Forks, North Dakota, 58201-4032
Heart Rhythm Associates PLLC
Greenville, North Carolina, 27834
Piedmont Cardiology Associates (Greenwood SC)
Greenwood, South Carolina, 29646
Hattiesburg Clinic/Forrest General
Hattiesburg, Mississippi, 39401
High Point Regional Health System
High Point, North Carolina, 27262
Saint Mary Medical Center (Community Healthcare System)
Hobart, Indiana, 46342
Edward N Shen MD Inc
Honolulu, Hawaii, 96813
Hall Garcia Cardiology Associates
Houston, Texas, 77030-2309
Apex Cardiology
Inglewood, California, 90301-4057
Borgess Medical Center
Kalamazoo, Michigan, 49048
Scripps Green Hospital Scripps Clinic Torrey Pines
La Jolla, California, 92037-1027
Clark & Daughtrey Medical Group PA
Lakeland, Florida, 33803
Cardiology Consultants of East Michigan
Lapeer, Michigan, 48446
Northern California Heart Care
Larkspur, California, 94939
Arkansas Cardiology PA (Little Rock AR)
Little Rock, Arkansas, 72205-6231
University Medical Associates
Louisville, Kentucky, 40202-1901
Macon Electrophysiology Associates PC
Macon, Georgia, 31201
Wisconsin Heart SC
Madison, Wisconsin, 53713-2319
Stark Medical Specialties Inc
Massillon, Ohio, 44646
Heart Clinic PLLC
McAllen, Texas, 78503
Melbourne Internal Medicine Associates / Century Research Associates
Melbourne, Florida, 32901
Memphis Heart Clinic
Memphis, Tennessee, 38120
Heart Consultants
Midwest City, Oklahoma, 73110
University of Minnesota
Minneapolis, Minnesota, 55455-0368
Mission Internal Medical Group
Mission Viejo, California, 92691-6384
James H Quillen VA Medical Center
Mountain Home, Tennessee, 37604
New Bedford Medical Associates
New Bedford, Massachusetts, 02740
New York Medical Center of Queens
New York, New York, 10001
Heartwise Cardiology
New York, New York, 10016
Arrhythmia Associates of New York
New York, New York, 10028-1802
Arrhythmia Institute
Newtown, Pennsylvania, 18940-1885
Medical Center Hospital Odessa
Odessa, Texas, 76761
Utah Cardiology (Ogden UT)
Ogden, Utah, 84405-7420
Terrance Khastgir MD PC
Oklahoma City, Oklahoma, 73112-4457
Heart Consultants PC
Omaha, Nebraska, 68122
Orange County Heart Institute & Research Center
Orange, California, 92868
C. Raghavan MD PA
Orlando, Florida, 32819
Foothill Cardiology
Pasadena, California, 91105
Saint Joseph's Regional Medical Center
Paterson, New Jersey, 07503
Northwest Florida Heart Group PA
Pensacola, Florida, 32514
Cardiology Consultants of Philadelphia
Philadelphia, Pennsylvania, 19107
Pacific Heart Associates
Portland, Oregon, 97227
Marshall-Rismiller & Associates
Pottsville, Pennsylvania, 17901
Wake Heart & Vascular Associates
Raleigh, North Carolina, 27610-1231
Desert Cardiology Center / Desert Cardiology Medical Group Consultants
Rancho Mirage, California, 92270
Baltimore Heart Associates (Randallstown MD)
Randallstown, Maryland, 21133-4707
Reno Heart Physicians
Reno, Nevada, 89503-4541
Virginia Cardiovascular Specialists PC
Richmond, Virginia, 23226-1928
Mayo Clinic
Rochester, Minnesota, 55905-0001
University Cardiovascular Associates (UCVA)
Rochester, New York, 14618-2663
Shady Grove Adventist Hospital
Rockville, Maryland, 20850
Heart & Vascular Institute of Florida
Safety Harbor, Florida, 34695-6604
Great Lakes Heart and Vascular Institute PC
Saint Joseph, Michigan, 49085
Saint Paul Cardiology
Saint Paul, Minnesota, 55102-1036
North Shore Cardiology Associates
Salem, Massachusetts, 01970
Peninsula Cardiology Associates
Salisbury, Maryland, 21804
Cardiology Clinic of San Antonio
San Antonio, Texas, 78229
Brett Berman Cardiology & Cardiac Electrophysiology
San Diego, California, 92103
Dwain L Coggins MD FACC
San Jose, California, 95124
Cardiovascular Consultants (Savannah GA)
Savannah, Georgia, 31404
Cardiology Associates of Schenectady PC
Schenectady, New York, 12304
Saint Catherine of Sienna Medical Center
Smithtown, New York, 11787-1628
Cardiovascular Clinical Associates PC
Southfield, Michigan, 48034
Ohio Institute of Cardiac Care Inc
Springfield, Ohio, 45504
Cardiology Consultants of Saint Louis County PC
St Louis, Missouri, 63128
Saint Louis Heart & Vascular PC
St Louis, Missouri, 63136-6111
Florida Cardiovascular Institute PA
Tampa, Florida, 33609
Cardiology Clinic of San Antonio
Tarzana, California, 91356
The Toledo Clinic
Toledo, Ohio, 43623-4231
Erol Kosar MD Inc
Torrance, California, 90503
Interventional Cardiac Consultants PLC
Trinity, Florida, 34655
Southern Arizona Health Care System
Tucson, Arizona, 85712-2836
Cardiovascular Associates of East Texas PA
Tyler, Texas, 75701
Arrhythmia Consultants of Milwaukee SC
Wauwatosa, Wisconsin, 53226-4362
Wilmington Cardiology LLC
Wilmington, North Carolina, 28403-5345
Forsyth Medical Center
Winston-Salem, North Carolina, 27103
Cardiology Associates
Woodland Park, New Jersey, 07424
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, 01655-0002
About this study
The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants. This study will assess therapies in Medtronic pacemaker, defibrillator, and cardiac resynchronization therapy devices.
The first therapy is for reducing unnecessary pacing in pacemaker patients. The second therapy provides pacing therapy in an attempt to stop fast or life threatening ventricular arrhythmias in lieu of delivering a defibrillation shock. The third therapy is a diagnostic measurement of a patient's fluid status and provides the physician information on the patient's heart failure status.
The study will also assess the time to a patient's first defibrillation shock and will verify that the shock was for a fast or life threatening ventricular rhythm.
Read the detailed description
The OMNI results demonstrate the importance of Medtronic's ongoing efforts to increase adoption of evidence based shock-reduction programming strategies. Longer VF NID (number of intervals to detect in the VF zone) should be utilized with the Anti-tachycardia Pacing (ATP) During Charging Feature. ATP during Charging allows physicians to treat with ATP without delay to shock. Therefore, VF NID may be extended to allow episodes the chance to self-terminate immediately to shock by use of the ATP during the charging feature.
- Conditions
- Tachycardia, Ventricular, Heart Failure, Congestive, Ventricular Fibrillation, Ventricular Dysfunction, Bradycardia
- Keywords
- Pacemaker, Defibrillator, Cardiac Resynchronization, Dysynchrony, Heart failure, Arrhythmia, Tachycardia, Bradycardia
- Medical subject headings
- Tachycardia, Ventricular, Heart Failure, Ventricular Fibrillation, Ventricular Dysfunction, Bradycardia, Arrhythmias, Cardiac, Tachycardia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Overall | All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implanted Systems Frequencies
Frequencies of implanted systems were measured among patients who were implanted with a device (IPT, ICD or CRT-D).
Measured: Baseline
Implantable Pulse Generator (IPG) Device Baseline Programming Frequencies.
Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P\&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost.
Measured: Baseline
ICD/CRT-D Device Baseline Programming Frequencies
ICD/CRT-D baseline programming, pacing mode and detection. Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P\&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost.
Measured: Baseline
ICD/CRT-D Device Baseline Programming Measurements
ICD/CRT-D baseline programming measurements, detection interval. Implanted Cardioverter/Defibrillator paces a patient's heart in a tachyarrhythmia prevention-pacing mode.
Detection intervals are used to detect atrial tachyarrhythmia. Detection Intervals are programmable heart rate thresholds. R-R intervals that are less than the VT or VF detection intervals (in ms) are considered evidence of VT or VF, respectively. R-R intervals that are between the FVT and the VF detection intervals are considered evidence of FVT. Thus, these detection interval thresholds demarcate rate zones of detection. The rate zones are used to determine the type of therapy applied once detection occurs.
Measured: Baseline
Secondary outcomes (5)
AV Block Status by Device Type at 6 and 12 Months.
Frequencies of subject with AV block over time between ICD and Implantable Pulse Generator(IPG) study participants.
Measured: 12 months post enrollment
AV Block Status by Severity of Historical AV Block
Frequencies of Subjects with AV Block Over Time by Severity of Historical AV Block
Measured: 4 years post implant
Summary of ATP Episodes Within All Treated Episodes
Evaluate the utility of the Antitachycardia Pacing (ATP) During Charging feature of the device.
Measured: 4 years post enrollment
Compare First Shock Rate Between Medtronic "PainFREE" Programming and "SCD-HeFT" Programming in Primary Prevention Study Participants.
First shock rate for VF and FVT zones was estimated using Kaplan-Meier method.
OMNI "PainFREE" definition: programming combinations that result in ATP therapy for ventricular tachycardia (VT) at cycle lengths <320 ms. Programming at cycle lengths ≥320 ms were not mandated.
OMNI "SCD-HeFT" definition: programming combinations that result in shock therapy only for arrhythmias at cycle lengths of <320 ms or faster and no therapy for arrhythmias at cycle lengths ≥320 ms.
Measured: 4 years post implant
Frequencies of Subjects With OptiVol Trends and Disease Progression.
Estimate the correlation between OptiVol trends and disease progression.
A subject's disease status was said to have progressed if:
- The NYHA classification number increases (example: I to II), or
- The LVEF decreases by at least 20% (relative difference) and by at least a 5% absolute difference, or
- The subject expires
A subject who crossed OptiVol threshold since last visit was regarded as 'crossed threshold'.
Measured: 4 years post implant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2006 (estimated)
- Study startAug 2005
- Primary completionNov 2010
- Study completionNov 2010
Why it stopped: Ended follow-up after four years
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Tachycardia, VentricularStudies of the same condition, open and under way.
- More trials run by Medtronic Cardiac Rhythm and Heart FailureThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 3,032 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Medtronic
- Responsible party
- Sponsor
- Investigators
- Michael O. Sweeney, Principal investigator, Cardiovascular Division Brigham and Womens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00277524
- Sponsor's protocol ID
- 601
- Acronym
- OMNI
- Status last verified
- May 2013
- First submitted
- 12 Jan 2006
- Last updated
- 28 Aug 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ; PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004 Oct 26;110(17):2591-6. doi: 10.1161/01.CIR.0000145610.64014.E4. Epub 2004 Oct 18.
PubMed 15492306Alpert JS. Are data from clinical registries of any value? Eur Heart J. 2000 Sep;21(17):1399-401. doi: 10.1053/euhj.2000.2265. No abstract available.
PubMed 10952831Lamas GA, Williams A. Have the results of randomized clinical trials of pacing altered the practice of cardiac pacing? J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S15-9. doi: 10.1046/j.1540-8167.14.s9.14.x.
PubMed 12950512Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399.
PubMed 15659722Liang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika, 1986, 73:13-22.
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.
- ClinicalTrials.gov ID
- NCT00277524
- Acronym / sponsor ID
- OMNI / 601
- Conditions
- Tachycardia, Ventricular, Heart Failure, Congestive, Ventricular Fibrillation, Ventricular Dysfunction, Bradycardia
- Keywords
- Pacemaker, Defibrillator, Cardiac Resynchronization, Dysynchrony, Heart failure, Arrhythmia, Tachycardia, Bradycardia
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Ended follow-up after four years
- Enrolment
- 3,032 participants (actual)
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailureIndustry (pharma, biotech, devices)
- Collaborators
- Medtronic
- Study start
- Aug 2005
- Primary completion
- Nov 2010 (actual)
- Study completion
- Nov 2010 (actual)
- First posted
- 16 Jan 2006 (estimated)
- Results
- Posted 28 Aug 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants. This study will assess therapies in Medtronic pacemaker, defibrillator, and cardiac resynchronization therapy devices.
The first therapy is for reducing unnecessary pacing in pacemaker patients. The second therapy provides pacing therapy in an attempt to stop fast or life threatening ventricular arrhythmias in lieu of delivering a defibrillation shock. The third therapy is a diagnostic measurement of a patient's fluid status and provides the physician information on the patient's heart failure status.
The study will also assess the time to a patient's first defibrillation shock and will verify that the shock was for a fast or life threatening ventricular rhythm.
Detailed description
The OMNI results demonstrate the importance of Medtronic's ongoing efforts to increase adoption of evidence based shock-reduction programming strategies. Longer VF NID (number of intervals to detect in the VF zone) should be utilized with the Anti-tachycardia Pacing (ATP) During Charging Feature. ATP during Charging allows physicians to treat with ATP without delay to shock. Therefore, VF NID may be extended to allow episodes the chance to self-terminate immediately to shock by use of the ATP during the charging feature.
Study design
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Overall | – | –All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients receiving a specified Medtronic Implantable Pulse Generator(IPG), Implantable Cardioverter Defibrillator(ICD), or Cardiac Resynchronization Therapy-Defibrillator(CRT-D) device where informed consent and/or authorization to use and disclose health information permission has been granted.
Key inclusion criteria (2 listed)
- Implant of new or replacement study device. Enrollment must occur no later than 40 days post-implant.
- Study participants must be 18 years of age or older.
Key exclusion criteria (2 listed)
- Study participants enrolled or intend to participate in another clinical device trial during the course of this study that required specific treatment or programming.
- Study participants unwilling and unable to comply with follow-up schedule.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Implanted Systems Frequencies
Time frame: Baseline
Frequencies of implanted systems were measured among patients who were implanted with a device (IPT, ICD or CRT-D).
Implantable Pulse Generator (IPG) Device Baseline Programming Frequencies.
Time frame: Baseline
Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P\&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost.
ICD/CRT-D Device Baseline Programming Frequencies
Time frame: Baseline
ICD/CRT-D baseline programming, pacing mode and detection. Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P\&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost.
ICD/CRT-D Device Baseline Programming Measurements
Time frame: Baseline
ICD/CRT-D baseline programming measurements, detection interval. Implanted Cardioverter/Defibrillator paces a patient's heart in a tachyarrhythmia prevention-pacing mode. Detection intervals are used to detect atrial tachyarrhythmia. Detection Intervals are programmable heart rate thresholds. R-R intervals that are less than the VT or VF detection intervals (in ms) are considered evidence of VT or VF, respectively. R-R intervals that are between the FVT and the VF detection intervals are considered evidence of FVT. Thus, these detection interval thresholds demarcate rate zones of detection. The rate zones are used to determine the type of therapy applied once detection occurs.
5 secondary outcomes
AV Block Status by Device Type at 6 and 12 Months.
Time frame: 12 months post enrollment
AV Block Status by Severity of Historical AV Block
Time frame: 4 years post implant
Summary of ATP Episodes Within All Treated Episodes
Time frame: 4 years post enrollment
Compare First Shock Rate Between Medtronic "PainFREE" Programming and "SCD-HeFT" Programming in Primary Prevention Study Participants.
Time frame: 4 years post implant
Frequencies of Subjects With OptiVol Trends and Disease Progression.
Time frame: 4 years post implant
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 15492306Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ; PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004 Oct 26;110(17):2591-6. doi: 10.1161/01.CIR.0000145610.64014.E4. Epub 2004 Oct 18.
- Background: PubMed 10952831Alpert JS. Are data from clinical registries of any value? Eur Heart J. 2000 Sep;21(17):1399-401. doi: 10.1053/euhj.2000.2265. No abstract available.
- Background: PubMed 12950512Lamas GA, Williams A. Have the results of randomized clinical trials of pacing altered the practice of cardiac pacing? J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S15-9. doi: 10.1046/j.1540-8167.14.s9.14.x.
- Background: PubMed 15659722Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399.
- BackgroundLiang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika, 1986, 73:13-22.
Related trials for Tachycardia, Ventricular
Enrolling by invitation
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters
Ventricular Arrhythmia
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
RecruitingObservational study
Genetic Markers of Cardiovascular Disease in Epilepsy
Epilepsy, Seizures
Recruiting
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
Tachycardia, Ventricular
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael O. Sweeney principal investigator
Cardiovascular Division Brigham and Womens
113 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tachycardia, Ventricular and Heart Failure, Congestive, run by Medtronic Cardiac Rhythm and Heart Failure at 113 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 28 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 113 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Aug 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implanted Systems Frequencies (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00277524, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2013.